Bioplatforms Australia is proud to partner with Therapeutic Innovation Australia (TIA), Microscopy Australia, Phenomics Australia, and ANSTO’s National Deuteration Facility (NDF) to support translational medical research through the Pipeline Accelerator voucher scheme.
The initiative, launched by TIA, tackles the medical products challenge identified in the 2021 National Research Infrastructure Roadmap. Through NCRIS, the scheme provides researchers and SMEs with access to cutting-edge facilities that span the full research pipeline: from molecular discovery to clinical trials.
The Pipeline Accelerator vouchers offset access costs to TIA, NDF and Phenomics Australia facilities. In this round, supplementary vouchers are also available for Bioplatforms Australia and Microscopy Australia, provided the application includes a TIA, NDF and/or Phenomics Australia voucher.
The program is designed to:
- Support experimental development often excluded from traditional grant funding
- Lower financial barriers for researchers and SMEs
- Increase awareness of NCRIS-supported capabilities
- Foster cross-disciplinary projects
- Build experience for early- and mid-career researchers
Key dates – 2025–26 Round 1
- Applications open: 7 September 2026
- Applications close: 30 October 2026, 5 pm (AEST)
- Assessment: November–December 2026
- Awards announced: December 2026
- Project start: Within 6 months of award
- Project completion: Within 12 months of commencement
The scheme values diversity and strongly encourages applications from early-career and female researchers.
Learn more about the program, read the guidelines, and apply via our project page.